PDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
Abstract
Authors
AJ Palmer WJ Valentine ME Minshall S Roze